Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Non-Current Debt (2024 - 2025)

Precision Biosciences (DTIL) has disclosed Non-Current Debt for 2 consecutive years, with $22.4 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt changed 0.37% to $22.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.4 million through Dec 2025, changed 0.37% year-over-year, with the annual reading at $22.4 million for FY2025, 0.37% changed from the prior year.
  • Non-Current Debt for Q4 2025 was $22.4 million at Precision Biosciences, roughly flat from $22.4 million in the prior quarter.
  • The five-year high for Non-Current Debt was $22.4 million in Q4 2025, with the low at $22.3 million in Q3 2024.